Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
Combined small-cell lung cancer (C-SCLC) is a relatively rare subtype of SCLC and is defined by the combination of SCLC and any elements of non-small-cell lung carcinoma. Anlotinib is a novel oral multitarget tyrosine kinase inhibitor that led to significant improvements in progression-free survival...
Guardado en:
Autores principales: | Yuying Gan, Pingli Liu, Tao Luo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/41409f0333584d9694d76c723d7253b2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study
por: Ying Liu, et al.
Publicado: (2021) -
Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu G, et al.
Publicado: (2021) -
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami S, et al.
Publicado: (2016) -
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Huanhuan Xu, et al.
Publicado: (2021) -
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Mengqiu Tang, et al.
Publicado: (2021)